Skip to main content
Premium Trial:

Request an Annual Quote

Maravai LifeSciences Acquires IP, Assets From Shuttered Molecular Assemblies

NEW YORK – Maravai LifeSciences said Tuesday that it has acquired intellectual property and relevant assets from enzymatic DNA synthesis firm Molecular Assemblies, which terminated the majority of its employees and ceased normal operations in November.

Financial details of the deal were not disclosed.

Maravai said the acquisition, which includes Molecular Assemblies' enzymatic synthesis technology, will enhance the mRNA and oligonucleotide manufacturing capabilities of its TriLink BioTechnologies subsidiary.

"Molecular Assemblies is the original leader in enzymatic oligo synthesis, with strong foundational IP," Maravai CEO Trey Martin said in a statement. "We plan to further evolve and enhance Molecular Assemblies’ workflows to push the limits of oligo length and purity, and to lower costs by vertically integrating NTPs and enzymes from our TriLink and Alphazyme businesses."

San Diego-based Maravai recently inked several deals for enzyme development. Last October, for example, Alphazyme, a unit of Maravai, inked a nonexclusive agreement with Codexis for licensing the latter's HiFi DNA polymerase, HiTemp reverse transcriptase, HiRev isothermal polymerase, and other enzymes for genomics and diagnostics applications.